Genetic Testing for Cutaneous Melanoma
Customize your policy alerts
Sign up for Presbyterian Health Plan Policy 7.7 alerts
Get alerted when Policy 7.7 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for molecular and gene-expression tests used to diagnose, characterize, or risk-stratify cutaneous melanoma. Coverage differs by product line, with Medicare and Medicaid coverage following applicable WPS or MolDX guidance and commercial testing generally considered experimental, investigational, or unproven.
As of the 08-27-2025 annual review, Medicare and Medicaid coverage continued for myPath Melanoma (0090U), DecisionDx DiffDx Melanoma (0314U), Pigmented Lesion Assay by DermTech (0089U), and DecisionDx Melanoma (81529).
DecisionDx Melanoma (81529) was moved from the exclusion section to covered status for Medicare and Medicaid, and its investigational and experimental configuration was removed for those lines of business.
Prior authorization is required for all four gene expression profiling tests for Medicare and Medicaid.
All four tests are non-covered for the Commercial line of business because leading oncology guidance considers the gene expression profiling tests investigational, experimental, or of uncertain clinical utility.
Pigmented Lesion Assay (0089U) was removed from the investigative policy and added to the applicable investigative and new technology policy for Medicare and Medicaid coverage.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.